Monitoring new long-lasting intravitreal formulation for glaucoma with vitreous images using optical coherence tomography
| Autor: | Elena García-Martín, Eugenio Vispe, Vicente Polo, Silvia Mendez-Martinez, José Cegoñino, Maria Jesus Rodrigo, Manuel Subias, José A. Mayoral, Alberto Montolío, Maria Jose Cardiel, José M. Fraile, Amaya Pérez del Palomar, Teresa Martinez-Rincon |
|---|---|
| Přispěvatelé: | Instituto de Salud Carlos III, Agencia Estatal de Investigación (España), Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), European Commission |
| Rok vydání: | 2021 |
| Předmět: |
Long lasting
medicine.medical_specialty intravitreal Monitoring genetic structures lcsh:RS1-441 Pharmaceutical Science Glaucoma Vitreous Article lcsh:Pharmacy and materia medica vitreous 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Optical coherence tomography Ophthalmology medicine 030304 developmental biology 0303 health sciences brimonidine Retinal pigment epithelium optical coherence tomography medicine.diagnostic_test business.industry allergology Brimonidine Retinal medicine.disease nanomedicine eye diseases Intensity (physics) Posterior segment of eyeball monitoring Nanomedicine medicine.anatomical_structure glaucoma chemistry Drug delivery drug delivery 030221 ophthalmology & optometry sense organs Intravitreal business Laponite medicine.drug |
| Zdroj: | Zaguán: Repositorio Digital de la Universidad de Zaragoza Universidad de Zaragoza Zaguán. Repositorio Digital de la Universidad de Zaragoza instname Pharmaceutics Digital.CSIC. Repositorio Institucional del CSIC Volume 13 Issue 2 Pharmaceutics, Vol 13, Iss 217, p 217 (2021) |
| Popis: | This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery. Intravitreal injection is the gold standard therapeutic option for posterior segment pathologies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF. This study was supported by Carlos III Health Institute, (grants numbers: M17/00213, PI17/01726, PI17/01946), and by MINECO/AEI/ERDF, EU (grants numbers: MAT2017-83858-C2-2). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|